Nucana presents encouraging data at asco gi for nuc-3373 in heavily pre-treated patients with metastatic colorectal cancer

Promising efficacy signals including a 62% disease control rate and a partial response in patients who had progressed on prior fluoropyrimidine therapy
NCNA Ratings Summary
NCNA Quant Ranking